[조사자료] 세계의 의약품 임상 시험 수탁 기관 (CRO) 서비스 시장 (~2028년)

■ 영문 제목 : Contract Research Organization (CRO) Services Market by Type (Early phase, Clinical, Lab, Consulting), Therapeutic Area (Oncology, Infectious Disease, Neurology, Immunology, Hematology, Vaccines, Cell & Gene Therapy), End User & Region - Global Forecast to 2028
	■ 상품코드 : PH4672-23 ■ 조사/발행회사 : MarketsandMarkets ■ 발행일 : 2023년 2월 ■ 페이지수 : 455 ■ 작성언어 : 영어 ■ 보고서 형태 : PDF ■ 납품 방식 : E메일 ■ 조사대상 지역 : 글로벌 ■ 산업 분야 : 의약품

■ 판매가격 / 옵션 (부가세 10% 별도)

Single User (1인 열람용)	USD4,950 ⇒환산￦6,682,500	견적의뢰/주문/질문
Five User (5인 열람용)	USD6,650 ⇒환산￦8,977,500	견적의뢰/주문/질문
Corporate License (동일 법인내 공유가능)	USD8,150 ⇒환산￦11,002,500	견적의뢰/구입/질문

※가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.

마켓츠앤마켓츠(MarketsandMarkets)는 세계의 의약품 임상 시험 수탁 기관 (CRO) 서비스 시장 규모가 2023년 766억 달러에서 2028년 1, 273억 달러에 이르며, 예측 기간 동안 연평균 10.7%로 성장할 것으로 예측하고 있습니다. 본 조사 보고서는 세계의 의약품 임상 시험 수탁 기관 (CRO) 서비스 시장을 조사 및 분석하여, 소개, 조사 수법, 개요, 프리미엄 인사이트, 시장 개요, 종류별 (임상 연구 서비스, 개발 초기 서비스, 실험실 서비스, 컨설팅 서비스, 데이터 관리 서비스) 분석, 치료 분야별 (종양, 감염증, 순환기 질환, 신경, 기타) 분석, 최종 용도별 (제약&바이오테크놀로지 기업, 의료 기기 제조 업체, 학술 기관) 분석, 지역별 (북미, 유럽, 아시아 태평양, 남미, 중동 및 아프리카) 분석, 경쟁 현황, 기업 정보 등의 항목을 게재하고 있습니다. 또한 본 조사 자료는 IQVIA (US) , LabCorp (US) , PPD (US) , Syneos Health (US) , WuXi AppTec (China) , Charles River Laboratories International (US) , Parexel International Corporation (US) , Pharmaron Beijing (China) , ICON (Ireland) , Medpace Holdings (US) , SGS (Switzerland) 등의 기업 정보를 포함하고 있습니다.
· 소개
· 조사 수법
· 개요
· 프리미엄 인사이트
· 시장 개요
· 세계의 의약품 임상 시험 수탁 기관 (CRO) 서비스 시장 규모 : 종류별
- 임상 연구 서비스의 시장 규모
- 개발 초기 서비스의 시장 규모
- 실험실 서비스의 시장 규모
- 컨설팅 서비스의 시장 규모
- 데이터 관리 서비스의 시장 규모
· 세계의 의약품 임상 시험 수탁 기관 (CRO) 서비스 시장 규모 : 치료 분야별
- 종양 치료에 사용되는 의약품 임상 시험 수탁 기관 (CRO) 서비스의 시장 규모
- 감염 치료에 사용되는 의약품 임상 시험 수탁 기관 (CRO) 서비스의 시장 규모
- 순환기 질환 치료에 사용되는 의약품 임상 시험 수탁 기관 (CRO) 서비스의 시장 규모
- 신경 치료에 사용되는 의약품 임상 시험 수탁 기관 (CRO) 서비스의 시장 규모
- 기타 치료 분야에 사용되는 의약품 임상 시험 수탁 기관 (CRO) 서비스의 시장 규모
· 세계의 의약품 개발 업무 수탁기관 (CRO) 서비스 시장 규모 : 최종 용도별
- 제약&바이오테크놀로지 기업에서 사용되는 의약품 임상 시험 수탁 기관 (CRO) 서비스의 시장 규모
- 의료 기기 제조업체에서 사용되는 의약품 임상 시험 수탁 기관 (CRO) 서비스의 시장 규모
- 학술 기관에서 사용되는 의약품 임상 시험 수탁 기관 (CRO) 서비스의 시장 규모
· 세계의 의약품 임상 시험 수탁 기관 (CRO) 서비스 시장 규모 : 지역별
- 북미의 의약품 임상 시험 수탁 기관 (CRO) 서비스 시장 규모
- 유럽의 의약품 임상 시험 수탁 기관 (CRO) 서비스 시장 규모
- 아시아 태평양의 의약품 임상 시험 수탁 기관 (CRO) 서비스 시장 규모
- 남미의 의약품 임상 시험 수탁 기관 (CRO) 서비스 시장 규모
- 중동의 및 아프리카의 의약품 임상 시험 수탁 기관 (CRO) 서비스스 시장 규모
· 경쟁 현황
· 기업 정보

■ 보고서 개요

“The global CRO services market in terms of revenue was estimated to be worth $76.6 billion in 2023 and is poised to reach $127.3 billion by 2028, growing at a CAGR of 10.7% from 2023 to 2028.”The global CRO services market is estimated to grow at a CAGR of 10.7% during the forecast period.　Growth in the CRO services market can mainly be attributed to factors such as the increasing investment in pharmaceutical R&D, the rising number of clinical trials, high cost of in-house drug development, which in turn is encouraging pharma-biotech companies to opt for outsourcing.

“The data management services segment accounted for the highest growth rate in the CRO services market, by type, during the forecast period”In 2022, the data management services segment accounted for the highest growth rate. The data management services segment is projected to grow at the highest CAGR owing to the factors such as the need to generate quality data for analysis and significance of data to meet the regulatory standards. Data management is gaining importance due to its role in the streamlined and uninterrupted development of drugs and medical devices.

“Asia Pacific: The fastest-growing region in the CRO services market”
The Asia Pacific market is estimated to record the highest CAGR during the forecast period. This is attributed to the rapid growth in the pharmaceutical and biopharmaceutical industries in the region and the relatively low cost of conducting clinical trials.

The primary interviews conducted for this report can be categorized as follows:
• By Respondent: Supply Side- 70% and Demand Side 30%
• By Designation: C-level – 45%, D-level – 30%, and Others – 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, Middle East & Africa- 5%

List of Companies Profiled in the Report:
• IQVIA (US)
• LabCorp (US)
• PPD (US)
• Syneos Health (US)
• WuXi AppTec (China)
• Charles River Laboratories International (US)
• Parexel International Corporation (US)
• Pharmaron Beijing (China)
• ICON (Ireland)
• Medpace Holdings (US)
• SGS (Switzerland)
• Frontage Holdings Corporation (US)
• PSI CRO (Switzerland)
• BioAgile Therapeutics (India)
• Firma Clinical Research (US)
• AccuLab Life Sciences (US)
• Novotech Health Holdings (Australia)
• KCR (US)
• Linical (Japan)
• Advanced Clinical (US)
• Azelix (US)
• Clinical Trial Service (Netherlands)
• Pepgra Healthcare (UK)
• Worldwide Clinical Trials Holdings (US)
• CTI Clinical Trial and Consulting Services (US)

Research Coverage:
This report provides a detailed picture of the global Contract Research Organization (CRO) Services Market. It aims at estimating the size and future growth potential of the market across different segments such as the service type, therapeutic area, end user and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall Contract Research Organization (CROs) Services Market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, challenges, trends, and opportunities.

■ 보고서 목차

1 INTRODUCTION 58
1.1 STUDY OBJECTIVES 58
1.2 MARKET DEFINITION 58
1.2.1 INCLUSIONS & EXCLUSIONS 59
1.3 MARKET SCOPE 60
FIGURE 1 CRO SERVICES MARKET SEGMENTATION 60
1.3.1 YEARS CONSIDERED 61
1.4 CURRENCY CONSIDERED 61
1.5 LIMITATIONS 61
1.6 STAKEHOLDERS 62
1.7 SUMMARY OF CHANGES 62
1.7.1 RECESSION IMPACT 63
2 RESEARCH METHODOLOGY 64
2.1 RESEARCH DATA 64
FIGURE 2 RESEARCH DESIGN 64
2.1.1 SECONDARY DATA 65
2.1.2 PRIMARY DATA 66
FIGURE 3 CRO SERVICES MARKET: BREAKDOWN OF PRIMARIES 66
2.2 MARKET SIZE ESTIMATION 67
FIGURE 4 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS, 2022 67
FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022 68
FIGURE 6 ILLUSTRATIVE EXAMPLE OF IQVIA: REVENUE SHARE ANALYSIS, 2022 68
2.2.1 INSIGHTS FROM PRIMARIES 70
FIGURE 7 MARKET VALIDATION FROM PRIMARY EXPERTS 70
FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 70
2.3 GROWTH FORECAST 71
FIGURE 9 CRO SERVICES MARKET: CAGR PROJECTIONS, 2023–2028 71
FIGURE 10 CRO SERVICES MARKET: GROWTH ANALYSIS OF DRIVERS, OPPORTUNITIES, AND CHALLENGES 72
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 73
FIGURE 11 DATA TRIANGULATION METHODOLOGY 73
2.5 RESEARCH ASSUMPTIONS 74
2.6 RISK ANALYSIS 74
2.7 RECESSION IMPACT ON CRO SERVICES MARKET 74
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH) 75
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION) 75
TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION) 75
3 EXECUTIVE SUMMARY 77
FIGURE 12 CRO SERVICES MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 77
FIGURE 13 CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2023 VS. 2028 (USD MILLION) 78
FIGURE 14 CRO SERVICES MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 79
FIGURE 15 GEOGRAPHICAL SNAPSHOT: CRO SERVICES MARKET 80
4 PREMIUM INSIGHTS 81
4.1 CRO SERVICES MARKET OVERVIEW 81
FIGURE 16 RISING INVESTMENTS IN PHARMACEUTICAL R&D TO DRIVE MARKET GROWTH 81
4.2 NORTH AMERICA: CRO SERVICES MARKET SHARE, BY TYPE & COUNTRY (2022) 82
FIGURE 17 CLINICAL RESEARCH SERVICES DOMINATED NORTH AMERICAN CRO SERVICES MARKET IN 2022 82
4.3 CRO SERVICES MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 83
FIGURE 18 CLINICAL RESEARCH SERVICES TO CONTINUE TO DOMINATE MARKET BY 2028 83
4.4 CRO SERVICES MARKET SHARE, BY END USER, 2022 83
FIGURE 19 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 83
4.5 CRO SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 84
FIGURE 20 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN CRO SERVICES MARKET FROM 2023 TO 2028 84
5 MARKET OVERVIEW 85
5.1 INTRODUCTION 85
5.2 MARKET DYNAMICS 85
FIGURE 21 CRO SERVICES MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES 85
TABLE 4 CRO SERVICES MARKET: IMPACT ANALYSIS 86
5.2.1 DRIVERS 86
5.2.1.1 Increasing drug R&D pipeline 86
FIGURE 22 ACTIVE PHARMACEUTICAL PIPELINE, 2012–2022 87
FIGURE 23 INCREASE IN GLOBAL PHARMACEUTICAL R&D SPENDING, 2014–2028 87
5.2.1.2 Technological advancements in clinical trials 88
5.2.1.3 High cost of in-house drug development 89
FIGURE 24 AVERAGE COST OF DEVELOPING PHARMACEUTICAL COMPOUNDS FROM DISCOVERY TO LAUNCH, 2010–2020 (USD BILLION) 89
5.2.2 OPPORTUNITIES 89
5.2.2.1 Need for novel clinical trial designs for complex cell & gene therapies 89
5.2.2.2 Emergence of hybrid models with CRO-CDMO partnerships 90
5.2.3 CHALLENGES 90
5.2.3.1 Patient recruitment and retention for clinical trials 90
5.2.3.2 Shortage of skilled professionals for clinical trials 90

5.3 MARKET TRENDS 91
5.3.1 INDUSTRY CONSOLIDATION 91
TABLE 5 LIST OF ACQUISITIONS 91
5.3.2 DECENTRALIZED CLINICAL TRIALS 92
5.3.3 REAL-WORLD DATA (RWD) AND REAL-WORLD EVIDENCE (RWE) 92
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 92
FIGURE 25 REVENUE SHIFT & NEW POCKETS FOR CRO SERVICE PROVIDERS 93
5.5 PRICING ANALYSIS 93
5.6 VALUE CHAIN ANALYSIS 94
FIGURE 26 VALUE CHAIN ANALYSIS OF CRO SERVICES MARKET: CLINICAL RESEARCH PHASE ADDS MAXIMUM VALUE 95
5.7 ECOSYSTEM ANALYSIS 95
FIGURE 27 ECOSYSTEM ANALYSIS: CRO SERVICES MARKET 96
TABLE 6 OVERALL MARKET ECOSYSTEM FOR CRO SERVICES 96
5.8 TECHNOLOGY ANALYSIS 98
5.9 CASE STUDY ANALYSIS 99
5.9.1 USING LAB DATA INSIGHTS TO IMPROVE POPULATION MANAGEMENT OF CHRONIC KIDNEY DISEASE (CKD) 99
5.9.2 IQVIA FOCUSES ON LEVERAGING AI AND ML TO IMPROVE SERVICE OFFERINGS 99
5.10 KEY CONFERENCES & EVENTS IN 2022–2023 99
TABLE 7 CRO SERVICES MARKET: DETAILED LIST OF CONFERENCES & EVENTS 99
5.11 REGULATORY ANALYSIS 101
5.11.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 101
TABLE 8 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 101
TABLE 9 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 102
TABLE 10 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 102
TABLE 11 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 103
5.12 PORTER’S FIVE FORCES ANALYSIS 106
TABLE 12 CRO SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS 106
5.12.1 THREAT FROM NEW ENTRANTS 107
5.12.2 THREAT FROM SUBSTITUTES 107
5.12.3 BARGAINING POWER OF BUYERS 107
5.12.4 BARGAINING POWER OF SUPPLIERS 107
5.12.5 DEGREE OF COMPETITION 108
5.13 KEY STAKEHOLDERS & BUYING CRITERIA 108
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 108
FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CRO SERVICES 108
5.13.2 BUYING CRITERIA FOR CRO SERVICES 109
FIGURE 29 KEY BUYING CRITERIA FOR END USERS 109
6 CRO SERVICES MARKET, BY TYPE 110
6.1 INTRODUCTION 111
TABLE 13 CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 111
6.2 CLINICAL RESEARCH SERVICES 112
TABLE 14 NUMBER OF REGISTERED AND RECRUITING CLINICAL STUDIES AS OF DECEMBER 2022, BY LOCATION 112
TABLE 15 EXAMPLES OF CLINICAL RESEARCH SERVICES OFFERED BY MARKET PLAYERS 112
FIGURE 30 DRUGS IN PIPELINE, BY DEVELOPMENT PHASE, 2021 VS. 2022 114
TABLE 16 CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2021–2028 (USD MILLION) 114
TABLE 17 CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 114
TABLE 18 NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 115
TABLE 19 EUROPE: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 115
TABLE 20 ASIA PACIFIC: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 116
TABLE 21 LATIN AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 116
6.2.1 PHASE III CLINICAL RESEARCH SERVICES 116
6.2.1.1 High cost of Phase III trials to drive demand for cost-effective CRO services 116
TABLE 22 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE III STUDIES 117
TABLE 23 PHASE III CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 117
TABLE 24 NORTH AMERICA: PHASE III CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 118
TABLE 25 EUROPE: PHASE III CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 118
TABLE 26 ASIA PACIFIC: PHASE III CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 119
TABLE 27 LATIN AMERICA: PHASE III CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 119
6.2.2 PHASE II CLINICAL RESEARCH SERVICES 119
6.2.2.1 Growing significance of Phase II studies to provide growth opportunities for CROs 119
TABLE 28 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE II STUDIES 120
TABLE 29 PHASE II CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 121
TABLE 30 NORTH AMERICA: PHASE II CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 31 EUROPE: PHASE II CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 122
TABLE 32 ASIA PACIFIC: PHASE II CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 122
TABLE 33 LATIN AMERICA: PHASE II CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 123
6.2.3 PHASE I CLINICAL RESEARCH SERVICES 123
6.2.3.1 Growing R&D pipeline of pharmaceutical companies to support growth 123
TABLE 34 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE I STUDIES 124
TABLE 35 PHASE I CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 124
TABLE 36 NORTH AMERICA: PHASE I CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 125
TABLE 37 EUROPE: PHASE I CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 125
TABLE 38 ASIA PACIFIC: PHASE I CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 126
TABLE 39 LATIN AMERICA: PHASE I CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 126
6.2.4 PHASE IV CLINICAL RESEARCH SERVICES 126
6.2.4.1 Increasing number of CROs providing post-marketing surveillance to boost market 126
TABLE 40 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE IV CLINICAL STUDIES 127
TABLE 41 PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 127
TABLE 42 NORTH AMERICA: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 128
TABLE 43 EUROPE: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 128
TABLE 44 ASIA PACIFIC: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 129
TABLE 45 LATIN AMERICA: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 129
6.3 EARLY-PHASE DEVELOPMENT SERVICES 129
FIGURE 31 DRUGS IN DEVELOPMENT, BY THERAPEUTIC AREA (2022) 130
TABLE 46 EXAMPLES OF EARLY-PHASE DEVELOPMENT SERVICES OFFERED BY MARKET PLAYERS 130
TABLE 47 EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 131
TABLE 48 EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 132
TABLE 49 NORTH AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 132
TABLE 50 EUROPE: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 132
TABLE 51 ASIA PACIFIC: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 133
TABLE 52 LATIN AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 133
6.3.1 CHEMISTRY, MANUFACTURING, AND CONTROLS SERVICES 133
6.3.1.1 Growing need to meet regulatory standards for drugs to drive demand for CMC services 133
TABLE 53 CHEMISTRY, MANUFACTURING, AND CONTROLS SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 134
TABLE 54 NORTH AMERICA: CHEMISTRY, MANUFACTURING, AND CONTROLS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 134
TABLE 55 EUROPE: CHEMISTRY, MANUFACTURING, AND CONTROLS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 135
TABLE 56 ASIA PACIFIC: CHEMISTRY, MANUFACTURING, AND CONTROLS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 135
TABLE 57 LATIN AMERICA: CHEMISTRY, MANUFACTURING, AND CONTROLS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 136
6.3.2 PRECLINICAL SERVICES 136
TABLE 58 PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 137
TABLE 59 PRECLINICAL SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 137
TABLE 60 NORTH AMERICA: PRECLINICAL SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 137
TABLE 61 EUROPE: PRECLINICAL SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 138
TABLE 62 ASIA PACIFIC: PRECLINICAL SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 138
TABLE 63 LATIN AMERICA: PRECLINICAL SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 138
6.3.2.1 Pharmacokinetics/Pharmacodynamics services 139
6.3.2.1.1 Importance of understanding interactions between body and administered drugs to drive uptake of PK/PD studies 139
TABLE 64 PHARMACOKINETICS/PHARMACOKINETICS SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 139
TABLE 65 NORTH AMERICA: PHARMACOKINETICS/PHARMACOKINETICS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 140
TABLE 66 EUROPE: PHARMACOKINETICS/PHARMACOKINETICS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 140
TABLE 67 ASIA PACIFIC: PHARMACOKINETICS/PHARMACOKINETICS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 141
TABLE 68 LATIN AMERICA: PHARMACOKINETICS/PHARMACOKINETICS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 141
6.3.2.2 Toxicology testing services 141
6.3.2.2.1 Need to prevent late-stage failures to boost demand for toxicology testing 141
TABLE 69 TOXICOLOGY TESTING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 142
TABLE 70 NORTH AMERICA: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 142
TABLE 71 EUROPE: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 143
TABLE 72 ASIA PACIFIC: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 143
TABLE 73 LATIN AMERICA: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 144
6.3.2.3 Other preclinical services 144
TABLE 74 OTHER PRECLINICAL SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 144
TABLE 75 NORTH AMERICA: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 145
TABLE 76 EUROPE: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 145
TABLE 77 ASIA PACIFIC: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 146
TABLE 78 LATIN AMERICA: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 146
6.3.3 DISCOVERY STUDIES 146
6.3.3.1 Increasing reliance on CRO services for target identification and validation to promote growth 146
TABLE 79 DISCOVERY STUDIES MARKET, BY REGION, 2021–2028 (USD MILLION) 147
TABLE 80 NORTH AMERICA: DISCOVERY STUDIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 147
TABLE 81 EUROPE: DISCOVERY STUDIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 147
TABLE 82 ASIA PACIFIC: DISCOVERY STUDIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 148
TABLE 83 LATIN AMERICA: DISCOVERY STUDIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 148
6.4 LABORATORY SERVICES 148
TABLE 84 EXAMPLES OF LABORATORY SERVICES OFFERED BY PROMINENT PLAYERS 149
TABLE 85 LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 149
TABLE 86 LABORATORY SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 150
TABLE 87 NORTH AMERICA: LABORATORY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 150
TABLE 88 EUROPE: LABORATORY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 150
TABLE 89 ASIA PACIFIC: LABORATORY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 151
TABLE 90 LATIN AMERICA: LABORATORY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 151
6.4.1 ANALYTICAL TESTING SERVICES 151
TABLE 91 ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 152
TABLE 92 ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 152
TABLE 93 NORTH AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 153
TABLE 94 EUROPE: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 153
TABLE 95 ASIA PACIFIC: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 154
TABLE 96 LATIN AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 154
6.4.1.1 Physical characterization services 154
6.4.1.1.1 Growing need to reduce risk of product failure to drive demand for physical characterization services 154
TABLE 97 PHYSICAL CHARACTERIZATION SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 155
TABLE 98 NORTH AMERICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 155
TABLE 99 EUROPE: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 156
TABLE 100 ASIA PACIFIC: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 156
TABLE 101 LATIN AMERICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 157
6.4.1.2 Raw material testing services 157
6.4.1.2.1 Need to ensure quality and purity of raw materials to support demand for raw material testing services 157
TABLE 102 RAW MATERIAL TESTING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 158
TABLE 103 NORTH AMERICA: RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 158
TABLE 104 EUROPE: RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 158
TABLE 105 ASIA PACIFIC: RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 159
TABLE 106 LATIN AMERICA: RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 159
6.4.1.3 Batch-release testing services 159
6.4.1.3.1 Comprehensive portfolio of batch-release testing services offered by CROs to propel growth 159
TABLE 107 BATCH-RELEASE TESTING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 160
TABLE 108 NORTH AMERICA: BATCH-RELEASE TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 160
TABLE 109 EUROPE: BATCH-RELEASE TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 161
TABLE 110 ASIA PACIFIC: BATCH-RELEASE TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 161
TABLE 111 LATIN AMERICA: BATCH-RELEASE TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 162
6.4.1.4 Stability testing services 162
6.4.1.4.1 Need to ensure long-term quality, safety, and efficacy of pharmaceutical products to boost uptake of stability testing 162
TABLE 112 STABILITY TESTING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 163
TABLE 113 NORTH AMERICA: STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 163
TABLE 114 EUROPE: STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 163
TABLE 115 ASIA PACIFIC: STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 164
TABLE 116 LATIN AMERICA: STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 164
6.4.1.5 Other analytical testing services 164
TABLE 117 OTHER ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 165
TABLE 118 NORTH AMERICA: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 165
TABLE 119 EUROPE: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 165
TABLE 120 ASIA PACIFIC: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 166
TABLE 121 LATIN AMERICA: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 166
6.4.2 BIOANALYTICAL TESTING SERVICES 166
6.4.2.1 Importance of accurate PK/PD studies to drive demand for bioanalytical testing services 166
TABLE 122 BIOANALYTICAL TESTING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 167
TABLE 123 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 167
TABLE 124 EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 168
TABLE 125 ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 168
TABLE 126 LATIN AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 169
6.5 CONSULTING SERVICES 169
6.5.1 GROWING ADOPTION OF CONSULTING SERVICES FOR FASTER AND MORE STREAMLINED REGULATORY APPROVALS TO BOOST MARKET 169
TABLE 127 EXAMPLES OF CONSULTING SERVICES OFFERED BY PROMINENT PLAYERS 170
TABLE 128 CONSULTING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 171
TABLE 129 NORTH AMERICA: CONSULTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 171
TABLE 130 EUROPE: CONSULTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 172
TABLE 131 ASIA PACIFIC: CONSULTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 172
TABLE 132 LATIN AMERICA: CONSULTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 173
6.6 DATA MANAGEMENT SERVICES 173
6.6.1 DATA MANAGEMENT SERVICES TO RECORD HIGHEST CAGR DURING FORECAST PERIOD 173
TABLE 133 EXAMPLES OF DATA MANAGEMENT SERVICES OFFERED BY PROMINENT PLAYERS 174
TABLE 134 DATA MANAGEMENT SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 174
TABLE 135 NORTH AMERICA: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 174
TABLE 136 EUROPE: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 175
TABLE 137 ASIA PACIFIC: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 175
TABLE 138 LATIN AMERICA: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 176
7 CRO SERVICES MARKET, BY THERAPEUTIC AREA 177
7.1 INTRODUCTION 178
TABLE 139 CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 178
7.2 ONCOLOGY 179
FIGURE 32 NUMBER OF ONCOLOGY CLINICAL TRIALS, 2012–2022 (THOUSAND) 179
TABLE 140 LIST OF FDA DRUGS APPROVED FOR ONCOLOGY (2022) 180
TABLE 141 NUMBER OF NEW CANCER CASES, BY TYPE, 2020 VS. 2040 180
TABLE 142 CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2021–2028 (USD MILLION) 181
TABLE 143 CRO SERVICES MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION) 181
TABLE 144 NORTH AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 181
TABLE 145 EUROPE: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 182
TABLE 146 ASIA PACIFIC: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 182
TABLE 147 LATIN AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 183
7.2.1 BREAST CANCER 183
7.2.1.1 High prevalence of breast cancer to drive market growth 183
TABLE 148 CRO SERVICES MARKET FOR BREAST CANCER, BY REGION, 2021–2028 (USD MILLION) 183
TABLE 149 NORTH AMERICA: CRO SERVICES MARKET FOR BREAST CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 184
TABLE 150 EUROPE: CRO SERVICES MARKET FOR BREAST CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 184
TABLE 151 ASIA PACIFIC: CRO SERVICES MARKET FOR BREAST CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 185
TABLE 152 LATIN AMERICA: CRO SERVICES MARKET FOR BREAST CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 185
7.2.2 LUNG CANCER 185
7.2.2.1 Increasing drug approvals to boost research on lung cancer 185
TABLE 153 CRO SERVICES MARKET FOR LUNG CANCER, BY REGION, 2021–2028 (USD MILLION) 186
TABLE 154 NORTH AMERICA: CRO SERVICES MARKET FOR LUNG CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 186
TABLE 155 EUROPE: CRO SERVICES MARKET FOR LUNG CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 187
TABLE 156 ASIA PACIFIC: CRO SERVICES MARKET FOR LUNG CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 187
TABLE 157 LATIN AMERICA: CRO SERVICES MARKET FOR LUNG CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 188
7.2.3 COLORECTAL CANCER 188
7.2.3.1 Increasing incidence of colorectal cancer to drive drug research activities worldwide 188
TABLE 158 CRO SERVICES MARKET FOR COLORECTAL CANCER, BY REGION, 2021–2028 (USD MILLION) 189
TABLE 159 NORTH AMERICA: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 189
TABLE 160 EUROPE: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 190
TABLE 161 ASIA PACIFIC: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 190
TABLE 162 LATIN AMERICA: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 191
7.2.4 PROSTATE CANCER 191
7.2.4.1 Increasing research initiatives on prostate cancer to drive growth 191
TABLE 163 CRO SERVICES MARKET FOR PROSTATE CANCER, BY REGION, 2021–2028 (USD MILLION) 192
TABLE 164 NORTH AMERICA: CRO SERVICES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 192
TABLE 165 EUROPE: CRO SERVICES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 192
TABLE 166 ASIA PACIFIC: CRO SERVICES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 193
TABLE 167 LATIN AMERICA: CRO SERVICES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 193
7.2.5 OTHER CANCERS 193
TABLE 168 CRO SERVICES MARKET FOR OTHER CANCERS, BY REGION, 2021–2028 (USD MILLION) 194
TABLE 169 NORTH AMERICA: CRO SERVICES MARKET FOR OTHER CANCERS, BY COUNTRY, 2021–2028 (USD MILLION) 194
TABLE 170 EUROPE: CRO SERVICES MARKET FOR OTHER CANCERS, BY COUNTRY, 2021–2028 (USD MILLION) 194
TABLE 171 ASIA PACIFIC: CRO SERVICES MARKET FOR OTHER CANCERS, BY COUNTRY, 2021–2028 (USD MILLION) 195
TABLE 172 LATIN AMERICA: CRO SERVICES MARKET FOR OTHER CANCERS, BY COUNTRY, 2021–2028 (USD MILLION) 195
7.3 INFECTIOUS DISEASES 195
7.3.1 INCREASING EPIDEMIC OUTBREAKS TO DRIVE DRUG DISCOVERY ACTIVITIES 195
TABLE 173 CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION) 196
TABLE 174 NORTH AMERICA: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 196
TABLE 175 EUROPE: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 197
TABLE 176 ASIA PACIFIC: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 197
TABLE 177 LATIN AMERICA: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 198
7.4 CARDIOVASCULAR SYSTEM DISORDERS 198
7.4.1 HIGH MORTALITY RATES TO COMPEL PHARMACEUTICAL COMPANIES TO DEVELOP NEW TREATMENT OPTIONS 198
TABLE 178 LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES (AS OF DECEMBER 2022) 198
TABLE 179 CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY REGION, 2021–2028 (USD MILLION) 199
TABLE 180 NORTH AMERICA: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 200
TABLE 181 EUROPE: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 200
TABLE 182 ASIA PACIFIC: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 201
TABLE 183 LATIN AMERICA: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 201
7.5 NEUROLOGY 201
7.5.1 INCREASING INVESTMENTS IN R&D FOR NEUROLOGICAL DISORDERS TO DRIVE MARKET 201
TABLE 184 LIST OF PIPELINE DRUGS FOR NEUROLOGICAL DISORDERS (2022) 202
TABLE 185 CRO SERVICES MARKET FOR NEUROLOGY, BY REGION, 2021–2028 (USD MILLION) 203
TABLE 186 NORTH AMERICA: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 203
TABLE 187 EUROPE: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 203
TABLE 188 ASIA PACIFIC: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 204
TABLE 189 LATIN AMERICA: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 204
7.6 VACCINES 204
7.6.1 NORMALIZATION OF VACCINES MARKET GROWTH TO PRE-COVID TIMES TO RESTRAIN MARKET GROWTH 204
TABLE 190 CRO SERVICES MARKET FOR VACCINES, BY REGION, 2021–2028 (USD MILLION) 205
TABLE 191 NORTH AMERICA: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION) 205
TABLE 192 EUROPE: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION) 206
TABLE 193 ASIA PACIFIC: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION) 206
TABLE 194 LATIN AMERICA: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION) 207

7.7 METABOLIC DISORDERS/ENDOCRINOLOGY 207
7.7.1 INCREASING GLOBAL DIABETES POPULATION TO BOOST MARKET 207
FIGURE 33 ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES, 2000–2045 (MILLION) 208
TABLE 195 CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY REGION, 2021–2028 (USD MILLION) 208
TABLE 196 NORTH AMERICA: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 209
TABLE 197 EUROPE: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 209
TABLE 198 ASIA PACIFIC: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 210
TABLE 199 LATIN AMERICA: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 210
7.8 IMMUNOLOGICAL DISORDERS 210
7.8.1 GROWING DRUG PIPELINE FOR IMMUNOLOGICAL DISORDERS TO FAVOR MARKET GROWTH 210
TABLE 200 LIST OF PIPELINE DRUGS FOR IMMUNOLOGICAL DISORDERS (2022) 211
TABLE 201 CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2021–2028 (USD MILLION) 211
TABLE 202 NORTH AMERICA: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 212
TABLE 203 EUROPE: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 212
TABLE 204 ASIA PACIFIC: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 213
TABLE 205 LATIN AMERICA: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 213
7.9 PSYCHIATRY 213
7.9.1 RISING INCIDENCE OF PSYCHIATRIC DISORDERS TO PROPEL GROWTH 213
TABLE 206 CRO SERVICES MARKET FOR PSYCHIATRY, BY REGION, 2021–2028 (USD MILLION) 214
TABLE 207 NORTH AMERICA: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2021–2028 (USD MILLION) 214
TABLE 208 EUROPE: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2021–2028 (USD MILLION) 215
TABLE 209 ASIA PACIFIC: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2021–2028 (USD MILLION) 215
TABLE 210 LATIN AMERICA: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2021–2028 (USD MILLION) 216
7.10 RESPIRATORY DISORDERS 216
7.10.1 GROWING BURDEN OF RESPIRATORY DISORDERS TO SUPPORT GROWTH 216
TABLE 211 LIST OF PIPELINE DRUGS FOR RESPIRATORY DISEASES (2022) 217
TABLE 212 CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY REGION, 2021–2028 (USD MILLION) 217
TABLE 213 NORTH AMERICA: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 218
TABLE 214 EUROPE: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 218
TABLE 215 ASIA PACIFIC: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 219
TABLE 216 LATIN AMERICA: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 219
7.11 DERMATOLOGY 219
7.11.1 GROWING DRUG DEVELOPMENT FOR VARIOUS SKIN DISORDERS TO PROPEL MARKET 219
TABLE 217 LIST OF PIPELINE DRUGS FOR SKIN DISEASES (2022) 220
TABLE 218 CRO SERVICES MARKET FOR DERMATOLOGY, BY REGION, 2021–2028 (USD MILLION) 220
TABLE 219 NORTH AMERICA: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 221
TABLE 220 EUROPE: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 221
TABLE 221 ASIA PACIFIC: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 222
TABLE 222 LATIN AMERICA: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 222
7.12 OPHTHALMOLOGY 222
7.12.1 GROWING OPHTHALMOLOGY-RELATED CLINICAL TRIALS TO DRIVE SEGMENT 222
TABLE 223 CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY REGION, 2021–2028 (USD MILLION) 223
TABLE 224 NORTH AMERICA: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 223
TABLE 225 EUROPE: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 223
TABLE 226 ASIA PACIFIC: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 224
TABLE 227 LATIN AMERICA: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 224
7.13 GASTROINTESTINAL DISEASES 224
7.13.1 GROWING R&D PIPELINE FOR GASTROINTESTINAL DISEASES TO AID GROWTH 224
TABLE 228 CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2021–2028 (USD MILLION) 225
TABLE 229 NORTH AMERICA: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 225
TABLE 230 EUROPE: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 226
TABLE 231 ASIA PACIFIC: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 226
TABLE 232 LATIN AMERICA: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 227

7.14 GENITOURINARY & WOMEN’S HEALTH 227
7.14.1 RISING PREVALENCE OF CHRONIC DISORDERS IN WOMEN TO PROPEL MARKET 227
TABLE 233 CRO SERVICES MARKET FOR GENITOURINARY AND WOMEN’S HEALTH, BY REGION, 2021–2028 (USD MILLION) 228
TABLE 234 NORTH AMERICA: CRO SERVICES MARKET FOR GENITOURINARY AND WOMEN’S HEALTH, BY COUNTRY, 2021–2028 (USD MILLION) 228
TABLE 235 EUROPE: CRO SERVICES MARKET FOR GENITOURINARY AND WOMEN’S HEALTH, BY COUNTRY, 2021–2028 (USD MILLION) 229
TABLE 236 ASIA PACIFIC: CRO SERVICES MARKET FOR GENITOURINARY AND WOMEN’S HEALTH, BY COUNTRY, 2021–2028 (USD MILLION) 229
TABLE 237 LATIN AMERICA: CRO SERVICES MARKET FOR GENITOURINARY AND WOMEN’S HEALTH, BY COUNTRY, 2021–2028 (USD MILLION) 230
7.15 HEMATOLO
7.16 OTHER THERAPEUTIC AREAS 232
TABLE 243 CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2021–2028 (USD MILLION) 233
TABLE 244 NORTH AMERICA: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 233
TABLE 245 EUROPE: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 234
TABLE 246 ASIA PACIFIC: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 234
TABLE 247 LATIN AMERICA: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 235
7.17 CUSTOMIZATION 235
7.17.1 CELL & GENE THERAPY 235
7.17.1.1 Favorable funding scenario for R&D to support growth 235
TABLE 248 CRO SERVICES MARKET FOR CELL & GENE THERAPY, BY REGION, 2021–2028 (USD MILLION) 236
TABLE 249 NORTH AMERICA: CRO SERVICES MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 237
TABLE 250 EUROPE: CRO SERVICES MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 237
TABLE 251 ASIA PACIFIC: CRO SERVICES MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 238
TABLE 252 LATIN AMERICA: CRO SERVICES MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 238
7.17.2 RARE DISEASES 238
7.17.2.1 Growth in drug R&D pipeline for rare diseases to drive market 238
TABLE 253 CRO SERVICES MARKET FOR RARE DISEASES, BY REGION, 2021–2028 (USD MILLION) 239
TABLE 254 NORTH AMERICA: CRO SERVICES MARKET FOR RARE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 239
TABLE 255 EUROPE: CRO SERVICES MARKET FOR RARE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 240
TABLE 256 ASIA PACIFIC: CRO SERVICES MARKET FOR RARE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 240
TABLE 257 LATIN AMERICA: CRO SERVICES MARKET FOR RARE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 241
7.17.3 BIOSIMILARS 241
7.17.3.1 Patent expiration of biologics to boost market 241
TABLE 258 CRO SERVICES MARKET FOR BIOSIMILARS, BY REGION, 2021–2028 (USD MILLION) 242
TABLE 259 NORTH AMERICA: CRO SERVICES MARKET FOR BIOSIMILARS, BY COUNTRY, 2021–2028 (USD MILLION) 242
TABLE 260 EUROPE: CRO SERVICES MARKET FOR BIOSIMILARS, BY COUNTRY, 2021–2028 (USD MILLION) 242
TABLE 261 ASIA PACIFIC: CRO SERVICES MARKET FOR BIOSIMILARS, BY COUNTRY, 2021–2028 (USD MILLION) 243
TABLE 262 LATIN AMERICA: CRO SERVICES MARKET FOR BIOSIMILARS, BY COUNTRY, 2021–2028 (USD MILLION) 243
TABLE 263 CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2021–2028 (USD MILLION) 244
7.17.3.2 Monoclonal antibodies 244
TABLE 264 CRO SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2021–2028 (USD MILLION) 244
TABLE 265 NORTH AMERICA: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 245
TABLE 266 EUROPE: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 245
TABLE 267 ASIA PACIFIC: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODIES BY COUNTRY, 2021–2028 (USD MILLION) 246
TABLE 268 LATIN AMERICA: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 246
7.17.3.3 Insulin 247
TABLE 269 CRO SERVICES MARKET FOR INSULIN, BY REGION, 2021–2028 (USD MILLION) 247
TABLE 270 NORTH AMERICA: CRO SERVICES MARKET FOR INSULIN, BY COUNTRY, 2021–2028 (USD MILLION) 247
TABLE 271 EUROPE: CRO SERVICES MARKET FOR INSULIN, BY COUNTRY, 2021–2028 (USD MILLION) 247
TABLE 272 ASIA PACIFIC: CRO SERVICES MARKET FOR INSULIN, BY COUNTRY, 2021–2028 (USD MILLION) 248
TABLE 273 LATIN AMERICA: CRO SERVICES MARKET FOR INSULIN, BY COUNTRY, 2021–2028 (USD MILLION) 248
7.17.3.4 CSF 249
TABLE 274 CRO SERVICES MARKET FOR CSF, BY REGION, 2021–2028 (USD MILLION) 249
TABLE 275 NORTH AMERICA: CRO SERVICES MARKET FOR CSF, BY COUNTRY, 2021–2028 (USD MILLION) 249
TABLE 276 EUROPE: CRO SERVICES MARKET FOR CSF, BY COUNTRY, 2021–2028 (USD MILLION) 249
TABLE 277 ASIA PACIFIC: CRO SERVICES MARKET FOR CSF, BY COUNTRY, 2021–2028 (USD MILLION) 250
TABLE 278 LATIN AMERICA: CRO SERVICES MARKET FOR CSF, BY COUNTRY, 2021–2028 (USD MILLION) 250
7.17.3.5 Erythropoietin 251
TABLE 279 CRO SERVICES MARKET FOR ERYTHROPOIETIN, BY REGION, 2021–2028 (USD MILLION) 251
TABLE 280 NORTH AMERICA: CRO SERVICES MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2021–2028 (USD MILLION) 251
TABLE 281 EUROPE: CRO SERVICES MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2021–2028 (USD MILLION) 252
TABLE 282 ASIA PACIFIC: CRO SERVICES MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2021–2028 (USD MILLION) 252
TABLE 283 LATIN AMERICA: CRO SERVICES MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2021–2028 (USD MILLION) 253
7.17.3.6 Other biosimilars 253
TABLE 284 CRO SERVICES MARKET FOR OTHER BIOSIMILARS, BY REGION, 2021–2028 (USD MILLION) 253
TABLE 285 NORTH AMERICA: CRO SERVICES MARKET FOR OTHER BIOSIMILARS, BY COUNTRY, 2021–2028 (USD MILLION) 253
TABLE 286 EUROPE: CRO SERVICES MARKET FOR OTHER BIOSIMILARS, BY COUNTRY, 2021–2028 (USD MILLION) 254
TABLE 287 ASIA PACIFIC: CRO SERVICES MARKET FOR OTHER BIOSIMILARS, BY COUNTRY, 2021–2028 (USD MILLION) 254
TABLE 288 LATIN AMERICA: CRO SERVICES MARKET FOR OTHER BIOSIMILARS, BY COUNTRY, 2021–2028 (USD MILLION) 255
8 CRO SERVICES MARKET, BY END USER 256
8.1 INTRODUCTION 257
TABLE 289 CRO SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 257
8.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 258
8.2.1 INCREASING R&D EXPENDITURE AND ROBUST PIPELINES TO DRIVE MARKET GROWTH 258
FIGURE 34 ANNUAL DRUG APPROVALS BY CDER (FDA), 2012–2021 258
FIGURE 35 R&D SPENDING OF PHRMA MEMBER COMPANIES, 2012–2021 259
TABLE 290 CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2021–2028 (USD MILLION) 260
TABLE 291 NORTH AMERICA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 260
TABLE 292 EUROPE: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 261
TABLE 293 ASIA PACIFIC: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 261
TABLE 294 LATIN AMERICA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 262
8.3 MEDICAL DEVICE COMPANIES 262
8.3.1 INCREASING R&D FOR DEVELOPMENT OF ADVANCED MEDICAL DEVICES TO SUPPORT GROWTH 262
FIGURE 36 US FDA DE NOVO MEDICAL DEVICE APPROVALS (2012–2022) 263
TABLE 295 CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2021–2028 (USD MILLION) 263
TABLE 296 NORTH AMERICA: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 264
TABLE 297 EUROPE: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 264
TABLE 298 ASIA PACIFIC: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 265
TABLE 299 LATIN AMERICA: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 265
8.4 ACADEMIC INSTITUTES 265
8.4.1 INCREASING COLLABORATIONS BETWEEN CROS AND ACADEMIC INSTITUTES TO BOOST MARKET 265
TABLE 300 CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2021–2028 (USD MILLION) 266
TABLE 301 NORTH AMERICA: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 267
TABLE 302 EUROPE: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 267
TABLE 303 ASIA PACIFIC: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 268
TABLE 304 LATIN AMERICA: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 268
9 CRO SERVICES MARKET, BY REGION 269
9.1 INTRODUCTION 270
TABLE 305 CRO SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 270
9.2 NORTH AMERICA 270
FIGURE 37 NORTH AMERICA: CRO SERVICES MARKET SNAPSHOT 271
TABLE 306 NORTH AMERICA: CRO SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 272
TABLE 307 NORTH AMERICA: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 272
TABLE 308 NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2021–2028 (USD MILLION) 272
TABLE 309 NORTH AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 273
TABLE 310 NORTH AMERICA: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 273
TABLE 311 NORTH AMERICA: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 273
TABLE 312 NORTH AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 274
TABLE 313 NORTH AMERICA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 274
TABLE 314 NORTH AMERICA: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION) 275
TABLE 315 NORTH AMERICA: CRO SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 275
9.2.1 US 275
9.2.1.1 US to dominate CRO services market in North America 275
FIGURE 38 DISTRIBUTION OF R&D COMPANIES, BY COUNTRY/REGION (2021 VS. 2022) 276
TABLE 316 US: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 277
TABLE 317 US: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2021–2028 (USD MILLION) 277
TABLE 318 US: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 278
TABLE 319 US: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 278
TABLE 320 US: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 278
TABLE 321 US: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 279
TABLE 322 US: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 279
TABLE 323 US: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION) 280
TABLE 324 US: CRO SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 280
9.2.2 CANADA 280
9.2.2.1 Favorable regulations to support market growth 280
TABLE 325 CANADA: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 281
TABLE 326 CANADA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2021–2028 (USD MILLION) 281
TABLE 327 CANADA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 282
TABLE 328 CANADA: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 282
TABLE 329 CANADA: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 282
TABLE 330 CANADA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 283
TABLE 331 CANADA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 283
TABLE 332 CANADA: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION) 284
TABLE 333 CANADA: CRO SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 284
9.2.3 NORTH AMERICA: RECESSION IMPACT 284
9.3 EUROPE 285
TABLE 334 EUROPE: CRO SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 285
TABLE 335 EUROPE: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 286
TABLE 336 EUROPE: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2021–2028 (USD MILLION) 286
TABLE 337 EUROPE: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 287
TABLE 338 EUROPE: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 287
TABLE 339 EUROPE: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 287
TABLE 340 EUROPE: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 288
TABLE 341 EUROPE: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 288
TABLE 342 EUROPE: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION) 289
TABLE 343 EUROPE: CRO SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 289
9.3.1 GERMANY 289
9.3.1.1 Growing outsourcing and government support to propel market 289
TABLE 344 GERMANY: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 290
TABLE 345 GERMANY: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2021–2028 (USD MILLION) 290
TABLE 346 GERMANY: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 291
TABLE 347 GERMANY: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 291
TABLE 348 GERMANY: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 291
TABLE 349 GERMANY: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 292
TABLE 350 GERMANY: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 292
TABLE 351 GERMANY: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION) 293
TABLE 352 GERMANY: CRO SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 293
9.3.2 UK 293
9.3.2.1 Investments by pharmaceutical sponsors for drug discovery services to boost market 293
FIGURE 39 UK: PHARMACEUTICAL R&D EXPENDITURE, 2011–2020 (USD MILLION) 294
TABLE 353 UK: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 295
TABLE 354 UK: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2021–2028 (USD MILLION) 295
TABLE 355 UK: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 295
TABLE 356 UK: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 296
TABLE 357 UK: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 296
TABLE 358 UK: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 296
TABLE 359 UK: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 297
TABLE 360 UK: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION) 297
TABLE 361 UK: CRO SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 298
9.3.3 FRANCE 298
9.3.3.1 Favorable drug research environment to drive market growth 298
TABLE 362 FRANCE: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 299
TABLE 363 FRANCE: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2021–2028 (USD MILLION) 299
TABLE 364 FRANCE: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 300
TABLE 365 FRANCE: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 300
TABLE 366 FRANCE: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 300
TABLE 367 FRANCE: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 301
TABLE 368 FRANCE: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 301
TABLE 369 FRANCE: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION) 302
TABLE 370 FRANCE: CRO SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 302
9.3.4 ITALY 302
9.3.4.1 Low drug approval time and growing research funding to fuel growth 302
TABLE 371 NUMBER OF CLINICAL TRIALS IN ITALY, BY COMPANY (JANUARY 2022) 303
TABLE 372 ITALY: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 303
TABLE 373 ITALY: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2021–2028 (USD MILLION) 303
TABLE 374 ITALY: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 304
TABLE 375 ITALY: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 304
TABLE 376 ITALY: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 304
TABLE 377 ITALY: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 305
TABLE 378 ITALY: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 305
TABLE 379 ITALY: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION) 306
TABLE 380 ITALY: CRO SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 306
9.3.5 SPAIN 306
9.3.5.1 Rising R&D expenditure to boost market 306
TABLE 381 SPAIN: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 307
TABLE 382 SPAIN: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2021–2028 (USD MILLION) 307
TABLE 383 SPAIN: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 308
TABLE 384 SPAIN: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 308
TABLE 385 SPAIN: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 308
TABLE 386 SPAIN: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 309
TABLE 387 SPAIN: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 309
TABLE 388 SPAIN: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION) 310
TABLE 389 SPAIN: CRO SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 310
9.3.6 REST OF EUROPE 310
TABLE 390 REST OF EUROPE: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 311
TABLE 391 REST OF EUROPE: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2021–2028 (USD MILLION) 312
TABLE 392 REST OF EUROPE: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 312
TABLE 393 REST OF EUROPE: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 312
TABLE 394 REST OF EUROPE: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 313
TABLE 395 REST OF EUROPE: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 313
TABLE 396 REST OF EUROPE: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 314
TABLE 397 REST OF EUROPE: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION) 314
TABLE 398 REST OF EUROPE: CRO SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 315
9.3.7 EUROPE: RECESSION IMPACT 315
9.4 ASIA PACIFIC 316
FIGURE 40 ASIA PACIFIC: CRO SERVICES MARKET SNAPSHOT 317
TABLE 399 ASIA PACIFIC: CRO SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 318
TABLE 400 ASIA PACIFIC: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 318
TABLE 401 ASIA PACIFIC: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2021–2028 (USD MILLION) 319
TABLE 402 ASIA PACIFIC: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 319
TABLE 403 ASIA PACIFIC: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 319
TABLE 404 ASIA PACIFIC: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 320
TABLE 405 ASIA PACIFIC: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 320
TABLE 406 ASIA PACIFIC: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 321
TABLE 407 ASIA PACIFIC: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION) 321
TABLE 408 ASIA PACIFIC: CRO SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 322
9.4.1 CHINA 322
9.4.1.1 China to dominate APAC CRO services market 322
TABLE 409 CHINA: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 323
TABLE 410 CHINA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2021–2028 (USD MILLION) 323
TABLE 411 CHINA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 324
TABLE 412 CHINA: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 324
TABLE 413 CHINA: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 324
TABLE 414 CHINA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 325
TABLE 415 CHINA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 325
TABLE 416 CHINA: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION) 326
TABLE 417 CHINA: CRO SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 326
9.4.2 JAPAN 326
9.4.2.1 Strong focus on research to drive market growth 326
TABLE 418 TOTAL NUMBER OF CLINICAL TRIALS IN JAPAN, BY THERAPEUTIC AREA, 2020 VS. 2022 327
TABLE 419 JAPAN: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 327
TABLE 420 JAPAN: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2021–2028 (USD MILLION) 327
TABLE 421 JAPAN: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 328
TABLE 422 JAPAN: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 328
TABLE 423 JAPAN: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 328
TABLE 424 JAPAN: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 329
TABLE 425 JAPAN: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 329
TABLE 426 JAPAN: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION) 330
TABLE 427 JAPAN: CRO SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 330
9.4.3 INDIA 330
9.4.3.1 Growing pharmaceutical industry to create favorable opportunities for market players 330
TABLE 428 INDIA: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 331
TABLE 429 INDIA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2021–2028 (USD MILLION) 331
TABLE 430 INDIA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 332
TABLE 431 INDIA: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 332
TABLE 432 INDIA: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 332
TABLE 433 INDIA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 333
TABLE 434 INDIA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 333
TABLE 435 INDIA: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION) 334
TABLE 436 INDIA: CRO SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 334
9.4.4 AUSTRALIA 334
9.4.4.1 Large number of research institutes to make Australia a favorable location for drug discovery 334
TABLE 437 AUSTRALIA: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 335
TABLE 438 AUSTRALIA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2021–2028 (USD MILLION) 335
TABLE 439 AUSTRALIA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 336
TABLE 440 AUSTRALIA: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 336
TABLE 441 AUSTRALIA: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 336
TABLE 442 AUSTRALIA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 337
TABLE 443 AUSTRALIA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 337
TABLE 444 AUSTRALIA: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION) 338
TABLE 445 AUSTRALIA: CRO SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 338
9.4.5 SOUTH KOREA 338
9.4.5.1 Government initiatives and growing R&D activities for drug development to drive growth 338
TABLE 446 SOUTH KOREA: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 339
TABLE 447 SOUTH KOREA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2021–2028 (USD MILLION) 339
TABLE 448 SOUTH KOREA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 340
TABLE 449 SOUTH KOREA: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 340
TABLE 450 SOUTH KOREA: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 340
TABLE 451 SOUTH KOREA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 341
TABLE 452 SOUTH KOREA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 341
TABLE 453 SOUTH KOREA: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION) 342
TABLE 454 SOUTH KOREA: CRO SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 342
9.4.6 REST OF ASIA PACIFIC (ROAPAC) 342
TABLE 455 REST OF ASIA PACIFIC: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 343
TABLE 456 REST OF ASIA PACIFIC: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2021–2028 (USD MILLION) 343
TABLE 457 REST OF ASIA PACIFIC: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 344
TABLE 458 REST OF ASIA PACIFIC: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 344
TABLE 459 REST OF ASIA PACIFIC: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 344
TABLE 460 REST OF ASIA PACIFIC: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 345
TABLE 461 REST OF ASIA PACIFIC: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 345
TABLE 462 REST OF ASIA PACIFIC: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION) 346
TABLE 463 REST OF ASIA PACIFIC: CRO SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 346
9.4.7 ASIA PACIFIC: RECESSION IMPACT 346
9.5 LATIN AMERICA 347
TABLE 464 LATIN AMERICA: CRO SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 347
TABLE 465 LATIN AMERICA: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 348
TABLE 466 LATIN AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2021–2028 (USD MILLION) 348
TABLE 467 LATIN AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 349
TABLE 468 LATIN AMERICA: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 349
TABLE 469 LATIN AMERICA: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 349
TABLE 470 LATIN AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 350
TABLE 471 LATIN AMERICA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 350
TABLE 472 LATIN AMERICA: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION) 351
TABLE 473 LATIN AMERICA: CRO SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 351
9.5.1 BRAZIL 351
9.5.1.1 Gradual growth in research to contribute to growth 351
TABLE 474 BRAZIL: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 352
TABLE 475 BRAZIL: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2021–2028 (USD MILLION) 352
TABLE 476 BRAZIL: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 353
TABLE 477 BRAZIL: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 353
TABLE 478 BRAZIL: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 353
TABLE 479 BRAZIL: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 354
TABLE 480 BRAZIL: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 354
TABLE 481 BRAZIL: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION) 355
TABLE 482 BRAZIL: CRO SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 355
9.5.2 REST OF LATIN AMERICA 355
TABLE 483 REST OF LATIN AMERICA: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 356
TABLE 484 REST OF LATIN AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2021–2028 (USD MILLION) 356
TABLE 485 REST OF LATIN AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 357
TABLE 486 REST OF LATIN AMERICA: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 357
TABLE 487 REST OF LATIN AMERICA: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 357
TABLE 488 REST OF LATIN AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 358
TABLE 489 REST OF LATIN AMERICA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 358
TABLE 490 REST OF LATIN AMERICA: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION) 359
TABLE 491 REST OF LATIN AMERICA: CRO SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 359
9.5.3 LATIN AMERICA: RECESSION IMPACT 359
9.6 MIDDLE EAST & AFRICA 360
9.6.1 GROWING PHARMACEUTICAL INDUSTRY TO DRIVE MARKET GROWTH 360
TABLE 492 MIDDLE EAST & AFRICA: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 360
TABLE 493 MIDDLE EAST & AFRICA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2021–2028 (USD MILLION) 361
TABLE 494 MIDDLE EAST & AFRICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 361
TABLE 495 MIDDLE EAST & AFRICA: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 361
TABLE 496 MIDDLE EAST & AFRICA: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 362
TABLE 497 MIDDLE EAST & AFRICA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 362
TABLE 498 MIDDLE EAST & AFRICA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 363
TABLE 499 MIDDLE EAST & AFRICA: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION) 363
TABLE 500 MIDDLE EAST & AFRICA: CRO SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 364
9.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 364
10 COMPETITIVE LANDSCAPE 365
10.1 INTRODUCTION 365
10.2 STRATEGIES ADOPTED BY KEY PLAYERS 366
FIGURE 41 CRO SERVICES MARKET: STRATEGIES ADOPTED BY KEY PLAYERS 366
10.3 REVENUE SHARE ANALYSIS 367
FIGURE 42 REVENUE ANALYSIS OF KEY PLAYERS, 2020–2022 367
10.4 MARKET SHARE ANALYSIS 367
FIGURE 43 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2022 368
TABLE 501 CRO SERVICES MARKET: DEGREE OF COMPETITION 368
10.5 COMPANY EVALUATION QUADRANT: KEY PLAYERS 369
FIGURE 44 CRO SERVICES MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022 370
10.5.1 STARS 370
10.5.2 EMERGING LEADERS 370
10.5.3 PERVASIVE PLAYERS 371
10.5.4 PARTICIPANTS 371
10.6 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS 371
10.6.1 INDUSTRY FOOTPRINT OF COMPANIES (25 COMPANIES) 371
TABLE 502 INDUSTRY FOOTPRINT ANALYSIS OF KEY PLAYERS IN CRO SERVICES MARKET 371
10.6.2 SERVICE FOOTPRINT OF COMPANIES (25 COMPANIES) 372
TABLE 503 SERVICE FOOTPRINT ANALYSIS OF KEY PLAYERS IN CRO SERVICES MARKET 372
10.6.3 REGIONAL FOOTPRINT OF COMPANIES (25 COMPANIES) 373
TABLE 504 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN CRO SERVICES MARKET 373
10.7 COMPANY EVALUATION QUADRANT: START-UPS/SMES 375
FIGURE 45 CRO SERVICES MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022 375
10.7.1 PROGRESSIVE COMPANIES 376
10.7.2 STARTING BLOCKS 376
10.7.3 RESPONSIVE COMPANIES 376
10.7.4 DYNAMIC COMPANIES 376
10.8 COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS 376
TABLE 505 CRO SERVICES MARKET: DETAILED LIST OF KEY START-UP/SME PLAYERS 376
TABLE 506 CRO SERVICES MARKET: COMPETITIVE BENCHMARKING OF START-UP/SMES 377
10.9 COMPETITIVE SCENARIOS AND TRENDS 378
10.9.1 SERVICE LAUNCHES 378
TABLE 507 CRO SERVICES MARKET: SERVICE LAUNCHES, JANUARY 2020–DECEMBER 2022 378
10.9.2 DEALS 379
TABLE 508 CRO SERVICES MARKET: DEALS, JANUARY 2020–DECEMBER 2022 379
10.9.3 OTHER DEVELOPMENTS 380
TABLE 509 CRO SERVICES MARKET: OTHER DEVELOPMENTS, JANUARY 2020–DECEMBER 2022 380
11 COMPANY PROFILES 381
11.1 KEY COMPANIES 381
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
11.1.1 IQVIA 381
TABLE 510 IQVIA: BUSINESS OVERVIEW 381
FIGURE 46 IQVIA: COMPANY SNAPSHOT (2021) 382
11.1.2 LABORATORY CORPORATION OF AMERICA HOLDINGS (LABCORP) 387
TABLE 511 LABORATORY CORPORATION OF AMERICA HOLDINGS: BUSINESS OVERVIEW 387
FIGURE 47 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2021) 388
11.1.3 PPD INC. (A PART OF THERMO FISHER SCIENTIFIC, INC.) 394
TABLE 512 PPD INC.: BUSINESS OVERVIEW 394
FIGURE 48 PPD INC.: COMPANY SNAPSHOT (2021) 395
11.1.4 SYNEOS HEALTH INC. 401
TABLE 513 SYNEOS HEALTH INC.: BUSINESS OVERVIEW 401
FIGURE 49 SYNEOS HEALTH INC.: COMPANY SNAPSHOT (2021) 402
11.1.5 WUXI APPTEC CO., LTD. 408
TABLE 514 WUXI APPTEC CO., LTD.: BUSINESS OVERVIEW 408
FIGURE 50 WUXI APPTEC CO., LTD.: COMPANY SNAPSHOT (2021) 409
11.1.6 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 414
TABLE 515 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: BUSINESS OVERVIEW 414
FIGURE 51 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT (2021) 415

11.1.7 PAREXEL INTERNATIONAL CORPORATION 420
TABLE 516 PAREXEL INTERNATIONAL CORPORATION: BUSINESS OVERVIEW 420
11.1.8 PHARMARON BEIJING CO., LTD. 426
TABLE 517 PHARMARON BEIJING CO., LTD.: BUSINESS OVERVIEW 426
FIGURE 52 PHARMARON BEIJING CO., LTD.: COMPANY SNAPSHOT (2021) 427
11.1.9 ICON PLC 430
TABLE 518 ICON PLC: BUSINESS OVERVIEW 430
FIGURE 53 ICON PLC: COMPANY SNAPSHOT (2021) 431
11.1.10 MEDPACE HOLDINGS, INC. 435
TABLE 519 MEDPACE HOLDINGS, INC.: BUSINESS OVERVIEW 435
FIGURE 54 MEDPACE HOLDINGS, INC.: COMPANY SNAPSHOT (2021) 436
11.1.11 SGS SA 438
TABLE 520 SGS SA: BUSINESS OVERVIEW 438
FIGURE 55 SGS SA: COMPANY SNAPSHOT (2021) 439
11.1.12 FRONTAGE HOLDINGS CORPORATION 442
TABLE 521 FRONTAGE HOLDINGS CORPORATION: BUSINESS OVERVIEW 442
FIGURE 56 FRONTAGE HOLDINGS CORPORATION: COMPANY SNAPSHOT (2021) 443
11.1.13 PSI CRO AG 447
TABLE 522 PSI CRO AG: BUSINESS OVERVIEW 447
11.1.14 BIOAGILE THERAPEUTICS PVT. LTD. 448
TABLE 523 BIOAGILE THERAPEUTICS PVT. LTD.: BUSINESS OVERVIEW 448
11.1.15 FIRMA CLINICAL RESEARCH, LLC 450
TABLE 524 FIRMA CLINICAL RESEARCH, LLC: BUSINESS OVERVIEW 450
11.1.16 ACCULAB LIFE SCIENCES 451
TABLE 525 ACCULAB LIFE SCIENCES: BUSINESS OVERVIEW 451
11.1.17 NOVOTECH HEALTH HOLDINGS 452
TABLE 526 NOVOTECH HEALTH HOLDINGS: BUSINESS OVERVIEW 452
11.1.18 KCR (FORMERLY KIECANA CLINICAL RESEARCH) 455
TABLE 527 KCR: BUSINESS OVERVIEW 455
11.1.19 LINICAL CO., LTD. 457
TABLE 528 LINICAL CO., LTD.: BUSINESS OVERVIEW 457
11.1.20 ADVANCED CLINICAL 459
TABLE 529 ADVANCED CLINICAL: BUSINESS OVERVIEW 459
11.2 OTHER PLAYERS 461
11.2.1 AZELIX LLC 461
11.2.2 CLINICAL TRIAL SERVICE BV 462
11.2.3 PEPGRA HEALTHCARE PVT. LTD. 463
11.2.4 WORLDWIDE CLINICAL TRIALS HOLDINGS INC. 464
11.2.5 CTI CLINICAL TRIAL AND CONSULTING SERVICES, INC. 466
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
12 APPENDIX 467
12.1 DISCUSSION GUIDE 467
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 471
12.3 CUSTOMIZATION OPTIONS 473
12.4 RELATED REPORTS 474
12.5 AUTHOR DETAILS 475

※본 조사보고서 [세계의 의약품 임상 시험 수탁 기관 (CRO) 서비스 시장 (~2028년)] (코드 : PH4672-23) 판매에 관한 면책사항을 반드시 확인하세요.

※본 조사보고서 [세계의 의약품 임상 시험 수탁 기관 (CRO) 서비스 시장 (~2028년)] 에 대해서 E메일 문의는 여기를 클릭하세요.

※당 사이트에 없는 보고서도 취급 가능한 경우가 많으니 문의 주세요!

[이하, 관련 보고서 소개]

글로벌 염기 교정 시장 (~2028년) : 플랫폼, 시약 및 키트, 플라스미드
BT8891-24 / MarketsandMarkets / 2023년 12월 / "글로벌 염기 교정 시장은 2023년 약 270백만 달러에서 2028년에는 549백만 달러에 달할 것으로 예상되며, 예측 기간 동안 15.2%의 CAGR을 기록할 것으로 예상됩니다."이 시장의 성장은 새로운 유전자 치료 및 개인 맞춤형...1. 서론 2. 조사 방법 3. 개요 4. 프리미엄 인사이트 5. 시장 개요 6. 세계의 염기 교정 시장 규모 : 제품 및 서비스별 7. 세계의 염기 교정 시장 규모 : 유형별 8. 세계의 염기 교정 시장 규모 : 표적 염기별 9. 세계의 염기 교정 시장 규모 : 용도별 10. 세계의...

글로벌 체외 독성 검사 시장 (~2028년) : 분석법 (ELISA, 웨스턴블롯), 기기, 소모품, 소프트웨어
BT2373-23 / MarketsandMarkets / 2023년 10월 / "세계의 체외 독성 검사 시장은 예측 기간 중 연평균 성장률 9.5%을 기록하여, 2023년 108억 달러에서 2028년 171억 달러에 이를 것으로 전망됩니다."이 시장의 성장은 독물학 기기의 기술적 진보, 조기 독성 검출을...1. 소개 2. 조사 방법 3. 개요 4. 프리미엄 인사이트 5. 시장 개요 6. 세계의 체외 독성 검사 시장 분석 : 제품 및 서비스별 7. 세계의 체외 독성 검사 시장 분석 : 독성 엔드포인트별 8. 세계의 체외 독성 검사 시장 분석 : 산업별 9. 세계의 체외 독성 검사 시장 분석...

글로벌 유전자 치료 시장 (~2028년) : 유전자 침묵, 유전자 증강
BT7506-23 / MarketsandMarkets / 2023년 10월 / "세계의 유전자 치료 시장은 2023년 90억 달러에서 2028년 239억 달러에 이르며, 예측 기간 중 연평균 성장률은 21.4%가 될 전망입니다."유전자 치료 시장의 성장을 촉진하는 주요 요인으로는 게놈 연구와 관련된 이니셔티브의 증가,...1. 소개 2. 조사 방법 3. 개요 4. 프리미엄 인사이트 5. 시장 개요 6. 세계의 유전자 치료 시장 분석 : 종류별 7. 세계의 유전자 치료 시장 분석 : 벡터별 8. 세계의 유전자 치료 시장 분석 : 치료 영역별 9. 세계의 유전자 치료 시장 분석 : 배달 방법별 10. 세계의 유전자...

글로벌 연속 바이오프로세싱 시장 (~2028년) : 크로마토그래피, 여과, 바이오 리액터, 배지
PH8866-24 / MarketsandMarkets / 2023년 11월 / "글로벌 연속 바이오프로세싱 시장은 2023년 218백만 달러에서 2028년에는 599백만 달러에 달할 것으로 예상되며, 2023년부터 2028년까지 예측 기간 동안 22.4%의 CAGR을 기록할 것으로 전망됩니다."이 시장의 성장은 CDMO와 CMO 사이에서 연속 바이오프로세싱의...1. 서론 2. 조사 방법 3. 개요 4. 프리미엄 인사이트 5. 시장 개요 6. 세계의 연속 바이오프로세싱 시장 규모 : 제품별 7. 세계의 연속 바이오프로세싱 시장 규모 : 사업 규모별 8. 세계의 연속 바이오프로세싱 시장 규모 : 프로세스별 9. 세계의 연속 바이오프로세싱 시장 규모 : 용도별 10. 세계의 연속 바이오프로세싱...

글로벌 후생 유전학 (에피제네틱스) 시장 (~2028년) : 효소 (DNA 변형 효소), 키트 및 시약 (항체), 기기, 소프트웨어
BT2775-24 / MarketsandMarkets / 2023년 12월 / "글로벌 후생 유전학 (에피제네틱스) 시장 규모는 2023년 18억 달러에서 2028년 43억 달러에 달할 것으로 예상되며, 예측 기간 동안 18.3%의 CAGR을 기록할 것으로 예상됩니다."시퀀싱 비용 및 시간 단축과 함께 연구개발에 대한...1. 서론 2. 조사 방법 3. 개요 4. 프리미엄 인사이트 5. 시장 개요 6. 세계의 후생 유전학 (에피제네틱스) 시장 규모 : 제품 및 서비스별 7. 세계의 후생 유전학 (에피제네틱스) 시장 규모 : 방법론별 8. 세계의 후생 유전학 (에피제네틱스) 시장 규모 : 기술별 9. 세계의 후생 유전학 (에피제네틱스) 시장 규모 :...